Aligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment

Aligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment

Show other versions (1)

Bibliografske podrobnosti
Main Authors:	Daniel J. Bromberg, Samy J. Galvez de Leon, Taylor Litz, Lyu Azbel, Amanda R. Liberman, Maxim Polonsky, Sergii Dvoriak, Nataliia Saichuk, Faye Taxman, Frederick L. Altice
Format:	Article
Jezik:	English
Izdano:	Public Library of Science (PLoS) 2023-01-01
Serija:	PLOS Global Public Health
Online dostop:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619786/?tool=EBI

Podobne knjige/članki

Aligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment.
od: Daniel J Bromberg, et al.
Izdano: (2023-01-01)

Measuring sustainability of opioid agonist therapy programs in the context of transition from Global Fund support
od: Raminta Stuikyte, et al.
Izdano: (2024-01-01)

Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey.
od: Daniel J Bromberg, et al.
Izdano: (2024-01-01)

Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey
od: Daniel J. Bromberg, et al.
Izdano: (2024-01-01)

Correction: Measuring sustainability of opioid agonist therapy programs in the context of transition from Global Fund Support
od: Raminta Stuikyte, et al.
Izdano: (2024-01-01)

High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
od: Samy J. Galvez, et al.
Izdano: (2023-11-01)

Corrigendum: High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
od: Samy J. Galvez, et al.
Izdano: (2024-01-01)

Opioid Agonist Treatment and Risk of Mortality During an Opioid Overdose Public Health Emergency: A Population-Based Retrospective Cohort Study
od: Lindsay A Pearce, et al.
Izdano: (2020-12-01)

The effect of opioid analgesics, benzodiazepines, gabapentinoids, and opioid agonist treatment on mortality risk among opioid-dependent people.
od: Chrianna Bharat, et al.
Izdano: (2022-08-01)

Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to opioid antagonism
od: Madigan L. Bedard, et al.
Izdano: (2024-06-01)

What is the benefit of inconsistent opioid agonist treatment in patients with prescription opioid use disorder?
od: R. Weiss, et al.
Izdano: (2023-03-01)

Sustainability of opioid agonist therapy programmes in Belarus, the Republic of Moldova, Tajikistan and Ukraine in the context of transition from Global Fund support during 2020–2023
od: Raminta Stuikyte, et al.
Izdano: (2024-10-01)

Oxytocin Reduces Noradrenergic-Induced Opioid-Like Withdrawal Symptoms in Individuals on Opioid Agonist Therapy
od: Brian J. Gully, et al.
Izdano: (2025-01-01)

Contextualizing medications for opioid use disorder and peer support service provision in the probation system with implementation science
od: Augustine W. Kang, et al.
Izdano: (2024-03-01)

Evaluating the Impact of Increased Dispensing of Opioid Agonist Therapy Take-Home Doses on Treatment Retention and Opioid-Related Harm among Opioid Agonist Therapy Recipients: A Simulation Study
od: Narjes Shojaati, et al.
Izdano: (2023-08-01)

Dynamics of agonist-evoked opioid receptor activation revealed by FRET- and BRET-based opioid receptor conformation sensors
od: Sina B. Kirchhofer, et al.
Izdano: (2025-02-01)

Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study
od: Anne Bouthillier, et al.
Izdano: (2025-02-01)

Challenges for the implementation of injectable opioid agonist treatment: a scoping review
od: Tanja Schwarz, et al.
Izdano: (2024-12-01)

Synthesis and Biological Evaluation of Novel Biased Mu-Opioid Receptor Agonists
od: Yanhao Guo, et al.
Izdano: (2024-06-01)

Evaluating comparative effectiveness of psychosocial interventions for persons receiving opioid agonist therapy for opioid use disorder: protocol for a systematic review
od: Brian Hutton, et al.
Izdano: (2018-10-01)

Artificial Intelligence (AI) .. Marketing touchpoints
od: Khalida ABI, et al.
Izdano: (2023-09-01)

Opioid crisis: a public health concern in Colorado, United States
od: Adeyemi A. Adeosun
Izdano: (2019-08-01)

Reframing the response to the opioid crisis: The critical role of resilience in public health
od: Roberts Donna L.
Izdano: (2024-01-01)

THE EFFECTS OF OPIOID AGONISTS AND ANTAGONISTS ON ATRIAL-NATRIURETIC-PEPTIDE (ANP) RELEASE IN MAN
od: Borges, F, et al.
Izdano: (1986)

Effect of 443c81, an inhaled mu-opioid receptor agonist in asthma.
od: Pavord, I, et al.
Izdano: (1994)

Novel Kappa-Opioid Receptor Agonist for the Treatment of Cholestatic Pruritus: Systematic Review
od: Adrian Joseph Michel Bailey, et al.
Izdano: (2022-05-01)

Intersecting epidemics of HIV, HCV, and syphilis among soon-to-be released prisoners in Kyrgyzstan: Implications for prevention and treatment
od: Azbel, L., et al.
Izdano: (2016)

Opioid and non-opioid analgesic regimens after fracture and risk of serious opioid-related events
od: Ashley A Leech, et al.
Izdano: (2024-04-01)

Strategies for supervising people with mental illnesses on probation caseloads: results from a nationwide study
od: Tonya B. Van Deinse, et al.
Izdano: (2023-10-01)

Opioid-independent and opioid-mediated modes of pain modulation
od: Berna, C, et al.
Izdano: (2018)

Corrigendum to “Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to opioid antagonism” [Addiction Neuroscience, Volume 11, June 2024, 100155]
od: Madigan L. Bedard, et al.
Izdano: (2024-09-01)

Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management
od: Wolfgang Sadee, et al.
Izdano: (2020-09-01)

Averting a UK opioid crisis: getting the public health messages ‘right’
od: Richards, GR, et al.
Izdano: (2022)

Comparing professional communities: Opioid prescriber networks and Public Health Preparedness Districts
od: Patrick Kaminski, et al.
Izdano: (2023-09-01)

Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review
od: Kimberly Corace, et al.
Izdano: (2019-12-01)

Hepatitis C virus elimination in Swiss opioid agonist therapy programmes – the SAMMSU cohort
od: Andrea Bregenzer, et al.
Izdano: (2021-03-01)

HCV elimination in a Swiss opioid agonist therapy programme – a cohort study
od: Andrea Bregenzer, et al.
Izdano: (2022-12-01)

Cantonal opioid agonist treatment authorisation systems – a mixed-method qualitative investigation
od: Caroline Schmitt-Koopmann, et al.
Izdano: (2024-06-01)

Delivery models of opioid agonist maintenance treatment in South Asia: a good beginning
od: Ravindra Rao, et al.
Izdano: (2013-02-01)

Delivery models of opioid agonist maintenance treatment in South Asia: a good beginning
od: Ravindra Rao, et al.